Substances of Human Origin (SoHO) legislation

EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.

Committees and units

The EHA Board sets up committees and units to perform specific tasks and activities.

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.

EHA Taskforce on Diversity, Equity, and Inclusion

The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:

Initiating and implementing activities to empower underrepresented groups.

2024 winners

EHA Kick-off Grants

The call for applications is closed. The EHA Kick-off Grant is a one-year grant intended to support basic and translational early career researchers in hematology.

Publications

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.

Chairs and Members

Chair (2017-present)Oliver A. Cornely—University Hospital Cologne, Cologne (Germany)

Co-chair (2023-present)Livio Pagano—Fondazione Policlinico A.

Master Class mentors

EHA-HKSH Hematology Tutorial

EHA is joining the Hong Kong Society of Hematology (HKSH) to organize the EHA-HKSH Hematology Tutorial on Lymphoid Malignancies.